Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivothym phase II trial in previously treated thymic carcinoma and type B3 thymoma
NL-OMON55734Phase 2Recruiting
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Apr 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and ipilimumab in thymic carcinoma (TC) and thymoma, sponsored by European Organisation for Research and Treatment of Cancer. Primary endpoint: Progression-free survival rate at 6 months. Started Apr 2019; status: recruiting.
02
Drugs
nivolumabipilimumab
03
Conditions
thymic carcinoma (TC)thymoma
Beyond the preview
Go deeper on NL-OMON55734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55734.